On the evening of April 10, Winner Medical Co.Ltd(300888) announced that in order to further enrich the company’s product line, expand business channels outside China and improve the company’s strategic layout, it plans to use its own funds of 728 million yuan to acquire a total of 55% equity of Longtai medical.
Winner Medical Co.Ltd(300888) said that the acquisition is highly consistent with Winner Medical Co.Ltd(300888) ‘s strategy of building a leader in the high-end wound dressing industry, and forms scale and synergy with the advantages of both sides in customers, markets, products, R & D and production.
It is reported that the main business of Longtai medical is high-end wound dressing. In 2021, Longtai medical sales revenue exceeded 350 million yuan, including silicone gel foam dressing and other high-end wound dressing and stoma products to achieve sales revenue of over 280 million yuan, and is in the leading position in China’s high-end wound dressing enterprises.
At present, China’s Hospital high-end wound dressing market is still in the initial stage of rapid growth. In the future, with the more comprehensive medical insurance coverage, the deepening understanding of doctors and nurses on products, and the upgrading of patients’ requirements for treatment effects, Chinese manufacturers have the advantages of production costs. It is expected that the market growth potential and import substitution space are huge.
Li Jianquan, chairman of Winner Medical Co.Ltd(300888) said: the most important reason why Winner Medical Co.Ltd(300888) and Longtai medical can go hand in hand is that both sides have a common mission and pursuit. I believe that the strong combination of Winner Medical Co.Ltd(300888) and Longtai medical will create a better future.
